💊
Ontilyv
opicapone
Parkinson Disease
ℹ️ Lapsed
✅
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Ontilyv is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
⚠️ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/ontilyv